The value of HRCT and Tc-depreotide in the evaluation of pulmonary lesions

Journal of Thoracic Oncology

Volumn 1, Issue 4, 2006, Pages 296-301

  Rasmussen, Karin ^a,b   Madsen, Hans H ^a   Rasmussen, Finn ^a   Rasmussen, Torben R ^a   Baandrup, Ulrik ^a   Pilegaard, Hans K ^a   Pedersen, Ulrik ^a   Palshof, Torben ^a   Rehling, Michael ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Department of Clinical Physiology and Nuclear Medicine ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DEPREOTIDE TC 99M; IODIXANOL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORODEOXYGLUCOSE F 18; SOMATOSTATIN; SOMATOSTATIN RECEPTOR; TECHNETIUM COMPLEX;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ECHOGRAPHY; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMAGE RECONSTRUCTION; LUNG CANCER; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; COMPUTER ASSISTED TOMOGRAPHY; LABORATORY DIAGNOSIS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; FALSE NEGATIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; RECEPTORS, SOMATOSTATIN; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34247270843     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200605000-00005     Document Type: Article

References (36)

1. Diederich S, Wormanns D, Semik M, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology 2002;222:773-781.
2. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99-105.
3. Pastorino U, Bellomi M, Landoni C, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 2003;362:593-597.
4. Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003;226:756-761.
5. Weisbrod GL. Transthoracic needle biopsy. World J Surg 1993;17:705-711.
6. Sanders C. Transthoracic needle aspiration. Clin Chest Med 1992;13:11-16.
7. Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 2003;123:115S-128S.
8. Furuya K, Murayama S, Soeda H, et al. New classification of small pulmonary nodules by margin characteristics on high-resolution CT. Acta Radiol 1999;40:496-504.
9. Seemann M.D., Seemann O, Luboldt W, et al. Differentiation of malignant from benign solitary pulmonary lesions using chest radiography, spiral CT and HRCT. Lung Cancer 2000;29:105-124.
10. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I- Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-731.
11. Kwekkeboom DJ, Kho GS, Lamberts SW, et al. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994;21:1106-1113.
12. Blum J, Handmaker H, Lister-James J, et al. A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;117:1232-1238.
13. Grewal RK, Dadparvar S, Yu JQ, et al. Efficacy of Tc-99m depreotide scintigraphy in the evaluation of solitary pulmonary nodules. Cancer J 2002;8:400-404.
14. Kahn D, Menda Y, Kernstine K, et al. The utility of (99m)Tc Depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer. Chest 2004;125:494-501.
15. Martins T, Lino JS, Ramos S, et al. 99mTc-Depreotide scintigraphy in the evaluation of indeterminate pulmonary lesions: clinical experience. Cancer Biother Radiopharmacol 2004;19:253-259.
16. Plachcinska A, Mikolajczak R, Maecke HR, et al. 99mTc-EDDA/HYNIC-TOC scintigraphy in the differential diagnosis of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 2004;31:1005-1010.
17. Baath M, Kolbeck KG, Danielsson R. Somatostatin receptor scintigraphy with 99mTc-Depreotide (NeoSpect) in discriminating between malignant and benign lesions in the diagnosis of lung cancer: a pilot study. Acta Radiol 2004;45:833-839.
18. Halley A, Hugentobler A, Icard P, et al. Efficiency of 18F-FDG and 99mTc-depreotide SPECT in the diagnosis of malignancy of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging
19. Chcialowski A, Dziuk E, From S, et al. Technetium99 labelled synthetic somatostatin analogue (depreotide) in the diagnosis of peripheral solitary pulmonary nodules. Pol Arch Med Wewn 2004;112:1031-1038.
20. Shon IH, O'Doherty MJ, Maisey MN. Positron emission tomography in lung cancer. Semin Nucl Med 2002;32:240-271.
21. Lichtenauer-Kaligis EG, Dalm VA, Oomen SP, et al. Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets. Eur J Endocrinol 2004;150:565-577.
22. Thomas LP, Balingit AG, Morison DS, et al. False-positive technetium 99m depreotide scintigraphy resulting from round atelectasis. J Thorac Imaging 2003;18:97-99.
23. Plachcinska A, Mikolajczak R, Kozak J, et al. A visual and semiquantitative assessment of (99m)Tc-EDDA/HYNIC-TOC scintigraphy in differentiation of solitary pulmonary nodules. Nucl Med Rev Cent East Eur 2004;7:143-150.
24. Quekel LG, Kessels AG, Goei R, et al. Miss rate of lung cancer on the chest radiograph in clinical practice. Chest 1999;115:720-724.
25. Reubi JC, Waser B, Sheppard M, et al. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF-receptors. Int J Cancer 1990;45:269-274.
26. O'Byrne KJ, Halmos G, Pinski J, et al. Somatostatin receptor expression in lung cancer. Eur J Cancer 1994;30A:1682-1687.
27. Fujita T, Yamaji Y, Sato M, et al. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. Life Sci 1994;55:1797-1806.
28. Virgolini I, Leimer M, Handmaker H, et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res 1998;58:1850-1859.
29. Traub T, Petkov V, Ofluoglu S, et al. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med 2001;42:1309-1315.
30. Denzler B, Reubi JC. Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 1999;85:188-198.
31. Plachcinska A, Mikolajczak R, Maecke H, et al. Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a pilot study. Cancer Biother Radiopharm 2004;19:261-270.
32. Adams S, Baum RP, Hertel A, et al. Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun 1998;19:641-647.
33. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075-1084.
34. Graeber GM, Gupta NC, Murray GF. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg 1999;117:719-727.
35. Knight SB, Delbeke D, Stewart JR, et al. Evaluation of pulmonary lesions with FDG-PET: comparison of findings in patients with and without a history of prior malignancy. Chest 1996;109:982-988.
36. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003;229:526-533.